Skip to main content
Premium Trial:

Request an Annual Quote

Roche Extends Takeover Offer for Illumina at Same Price

NEW YORK (GenomeWeb News) – Roche has extended its $5.7 billion hostile takeover bid for Illumina for another month at the same price, the company said today.

Roche's offer for Illumina, at $44.50 per share, was set to expire on March 23. The company has now extended it to April 20 at 6 pm EDT, keeping all terms and conditions the same. This is the second time Roche has prolonged the offer, which originally expired Feb. 24.

The offer will now be valid until after Illumina's annual shareholder meeting on April 18. During that meeting, shareholders will elect four members of Illumina's board of directors and vote on a proposal by Roche to expand the board by two members. Roche hopes to fill all open board positions with its own candidates.

Roche said that 144,208 shares had been tendered as of March 23, including 102 shares guaranteed to be delivered within the next three Nasdaq trading days.

The company made its original bid to acquire all outstanding shares of Illumina in cash on Jan. 27. Illumina's board unanimously rejected the offer in February, calling it "grossly inadequate," and has been urging its shareholders to vote against Roche's board nominees and board expansion plan.

Illumina issued a statement today after Roche extended its offer, saying, "Illumina is positioned to create far more value than Roche has offered. Our stockholders clearly agree."

In mid-morning trading today on the Nasdaq, shares of Illumina inched up 1 percent to $49.83.

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.